Global Candidiasis Drugs Market 2019-2023
- January 2019 •
- 124 pages •
- Report ID: 5731033 •
- Format: PDF
Advances in diagnosis of antifungal resistant pathogens to drive market growth. Although the currently available antifungal drugs are killing various species of candidiasis, some fungi can develop the ability to defend these drugs. For instance, Candida auris, an emerging antifungal¬resistant yeast, is frequently resistant to multiple antifungal drugs that were used to treat Candida infections. Moreover, it can cause serious bloodstream infections in hospitalized patients. Hence, advanced technologies are required for the diagnosis of such fungal diseases caused by antifungal¬resistant pathogens. Technavio’ s analysts have predicted that the candidiasis drugs market will register a CAGR of almost 4% by 2023.
Rising awareness about candidiasis
The signs and symptoms of candidiasis are very broad, and they also depend on the type of candidiasis infection. They sometimes resemble the symptoms of other diseases caused by bacteria. Hence, confirmatory diagnosis methods are required to confirm the disease after assessing the initial symptoms. Early detection can aid in treating them more effectively. Therefore, to create awareness about the disease and treatment options and avoid delay in diagnosis, the CDC is providing information about candidiasis, and its causes, risk factors, transmission, diagnosis, and treatment in the US.
Side effects of available drugs
Although several off-label medications are available for the symptomatic treatment of candidiasis, the side effects associated with them are decreasing their preference. For instance, polyene antifungal medicine, nystatin causes mouth irritation, diarrhea, nausea, vomiting, stomach upset, rashes, hives, and skin irritation. Although azole medications such as fluconazole, voriconazole, and miconazole are usually well tolerated, they cause side effects such as a headache, nausea, abdominal pain, diarrhea, vomiting, dyspepsia, liver damages, and rashes.
For the detailed list of factors that will drive and challenge the growth of the candidiasis drugs market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Merck and Pfizer the competitive environment is quite intense. Factors such as the advances in diagnosis of antifungal resistant pathogens and the rising awareness about candidiasis, will provide considerable growth opportunities to candidiasis drugs manufactures. Astellas Pharma, Bayer, Fresenius, Merck, and Pfizer are some of the major companies covered in this report.